Form 4: United Therapeutics COO Sells Shares After Option Exercise

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and subsequently sold 22,500 shares of common stock for approximately $473.66 per share.

Summary

• Michael Benkowitz, President and COO of United Therapeutics Corp (UTHR), executed a series of transactions on November 24, 2025.
• These transactions involved the exercise of stock options and the subsequent sale of the resulting common stock.
• A total of 22,500 shares were acquired through option exercises at prices ranging from $117.76 to $146.03 per share.
• All 22,500 acquired shares were then sold at a price of $473.6569 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan established by Mr. Benkowitz on June 3, 2025.
• The shares were held indirectly through two separate trusts, one beneficially owned by the Reporting Person (with spouse as co-trustee) and another beneficially owned by the Reporting Person's family members (with Reporting Person having sole investment and voting power).

Sentiment

Score: 6

Explanation: The filing details a pre-planned monetization of executive compensation through option exercise and subsequent share sale. This is a routine event for executives and, while it represents insider selling, the pre-planned nature under a 10b5-1 plan mitigates concerns about reactive selling based on negative undisclosed information. The significant profit realized by the insider (sale price of ~$473 vs. exercise prices of ~$117-$146) reflects the company's stock appreciation, which is generally positive for shareholders.

Positives

• The significant difference between the option exercise prices ($117.76, $135.42, $146.03) and the sale price ($473.6569) indicates substantial value creation for the executive from their compensation, reflecting the company's stock appreciation.
• The transactions were executed under a Rule 10b5-1 trading plan, suggesting a pre-planned and systematic approach to monetizing vested compensation rather than a reactive sale based on new, undisclosed information.

Negatives

• Insider selling, even when pre-planned, can sometimes be perceived negatively by some market participants, although it is a common practice for executives to diversify holdings and realize compensation.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on June 3, 2025.

Industry Context

This is a routine insider transaction common in the pharmaceutical and biotechnology industry, where executive compensation often includes stock options that are monetized upon vesting. It does not reflect broader industry trends or competitive positioning.

Related Party Transactions

• The transactions involved shares held in a trust where the Reporting Person is a beneficiary and co-trustee, having shared investment and voting power with their spouse.
• Additional transactions involved shares held in a trust where the Reporting Person's family members are beneficiaries, and the Reporting Person has sole investment and voting power.

Stakeholder Impact

• Shareholders may note the insider selling, but the pre-planned nature under a Rule 10b5-1 plan typically reduces concerns about the executive's confidence in the company's future.
• The executive, Michael Benkowitz, has realized significant personal gains from the appreciation of United Therapeutics' stock, reflecting the value of his compensation package.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction (exercise of options and sale of shares) by the President and COO. Such transactions are common for executive compensation and do not typically signal a change in the company's fundamental outlook or performance. The sale was executed under a Rule 10b5-1 trading plan, indicating it was scheduled in advance rather than being a reactive decision based on new information. Therefore, this filing alone does not provide a basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it doesn't alter the investment thesis.

Keywords

United Therapeutics, UTHR, Insider Trading, Form 4, Stock Options, Share Sale, Executive Compensation, Michael Benkowitz, 10b5-1 Plan